Breaking Finance News

A statement released earlier today by Piper Jaffray Cos. about Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) bumps the target price to $4.00

Boasting a price of $1.12, Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) traded 28.57% higher on the day. With the last stock price close up 64.33% from the two hundred day average, compared with the S&P 500 Index which has decreased -0.01% over the date range. Catalyst Pharmaceuticals Inc has recorded a 50-day average of $1.04 and a two hundred day average of $0.88. Volume of trade was up over the average, with 3,046,347 shares of CPRX changing hands over the typical 770,974

Piper Jaffray Cos. bumped up the target of Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) to $4.00 stating a potential upside of 2.57%.

Performance Chart

Catalyst Pharmaceuticals Inc (NASDAQ:CPRX)

With a total market value of $0, Catalyst Pharmaceuticals Inc has with a one year low of $0.51 and a one year high of $3.55 .

A total of 4 equity analysts have released a ratings update on CPRX. zero equity analysts rating the company a strong buy, four equity analysts rating the company a buy, zero equity analysts rating the company a hold, zero equity analysts rating the company a underperform, and finally zero equity analysts rating the company a sell with a one year target of $6.81.

Brief Synopsis About Catalyst Pharmaceuticals Inc (NASDAQ:CPRX)

Catalyst Pharmaceuticals, Inc., formerly Catalyst Pharmaceutical Partners, Inc., is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115. The Company's Firdapse is indicated for the treatments of lambert-eaton myasthenic syndrome (LEMS) and congenital myasthenic syndromes (CMS). Firdapse consists of the phosphate salt of amifampridine. The Company has completed the Phase III trial of Firdapse. The Company's CPP-109 (vigabatrin) is a gamma-aminobutyric acid (GABA) aminotransferase inhibitor. CPP-109 is indicated for the treatment of Tourette's Disorder. The Company's CPP-115 is a GABA aminotransferase inhibitor. CPP-115 is indicated for the treatment of selected neurological indications, such as complex partial seizures and Tourette's Disorder, and epilepsy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.